Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Second TKI Discontinuation in CML Patients That Failed First Discontinuation and Subsequently Regained Deep Molecular Response after TKI Re-Challenge

Thomas Pagliardini, Franck E. Nicolini, MD PhD, Stephane Giraudier, MD PhD, Philippe Rousselot, Gabriel Etienne, MD PhD, Françoise Huguet, MD, Agnes Guerci-Bresler, MD PhD, Bruno R. Varet, MDPhD, Martine Escoffre, MD, Stephane Morisset, Stat, Francois-Xavier Mahon, Laurence Legros, MD PhD

Blood (2016) 128 (22): 788.

https://doi.org/10.1182/blood.V128.22.788.788

Published: 2016

Journal Articles

Frontline Therapy with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Induction Followed By Autologous Stem Cell Transplantation, Krd Consolidation and Lenalidomide Maintenance in Newly Diagnosed Multiple Myeloma (NDMM) Patients: Primary Results of the Intergroupe Francophone Du MyéLome (IFM) Krd Phase II Study

Murielle Roussel, MD, Valerie Lauwers-Cances, MD, Nelly Robillard, PhD, Karim Belhadj, MD, Thierry Facon, MD PhD, Laurent Garderet, MD, Martine Escoffre, MD, Brigitte Pegourie, MD, Lotfi Benboubker, MD PhD, Denis Caillot, Cecile Fohrer, MD, Philippe Moreau, Xavier Leleu, Herve Avet-Loiseau, MD PhD, Michel Attal

Blood (2016) 128 (22): 1142.

https://doi.org/10.1182/blood.V128.22.1142.1142

Published: 2016

Journal Articles

Dasatinib or Nilotinib Discontinuation in Chronic Phase (CP)-Chronic Myeloid Leukemia (CML) Patients (pts) with Durably Undetectable BCR-ABL Transcripts: Interim Analysis of the STOP 2G-TKI Study with a Minimum Follow-up of 12 Months – on Behalf of the French CML Group Filmc

Delphine Rea, MD PhD, Franck E. Nicolini, MD PhD, Michel Tulliez, MD, Philippe Rousselot, MD, Francois Guilhot, MD, Martine Gardembas, MD, Agnès Guerci, MD, Valérie Coiteux, MD, Laurence Legros, MD PhD, Gaelle Guillerm, MD, Jean Michel Pignon, MD, Stephane Giraudier, MD PhD, Gabriel Etienne, Bruno Villemagne, MD, Martine Escoffre, MD, Aude Charbonnier, MD PhD, Francois-Xavier Mahon, MD PhD

Blood (2014) 124 (21): 811.

https://doi.org/10.1182/blood.V124.21.811.811

Published: 2014

Journal Articles

Preliminary Report Of The STIM2 Study: A Multicenter Stop Imatinib Trial For Chronic Phase Chronic Myeloid Leukemia De Novo Patients On Imatinib

Francois-Xavier Mahon, MD, PhD, Franck E. Nicolini, MD, PhD, Marie-Pierre Noël, MD, Martine Escoffre, MD, Aude Charbonnier, MD, Delphine Rea, MD, PhD, Viviane Dubruille, Bruno R. Varet, MD, Laurence Legros, MD, PhD, Agnès Guerci, MD, Gabriel Etienne, MD, PHD, Francois Guilhot, MD, Stéphanie Dulucq, PharmD, Philippe Rousselot, MD, PhD, Joelle Guilhot, PhD

Blood (2013) 122 (21): 654.

https://doi.org/10.1182/blood.V122.21.654.654

Published: 2013

Journal Articles

Post-Remission Therapy with Imatinib and HAM Improve MRD before Tansplant for Patients with Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ALL): Results of the GRAALL AFR03 Study.

Thibaut Leguay, MD, Francis Witz, MD, Stéphane De Botton, MD, Jean Gabert, MD PHD, Jean-Michel Cayuela, MD PHD, Elizabeth Macintyre, MD PHD, Claude Preudhomme, MD, Nathalie Fegueux, MD, Xavier Thomas, MD, Jean-Yves Cahn, MD, Martine Escoffre, MD, Andre Delannoy, MD, Norbert Ifrah, MD, Herve Dombret, MD, Arnaud Pigneux, MD

Blood (2006) 108 (11): 1877.

https://doi.org/10.1182/blood.V108.11.1877.1877

Published: 2006

Journal Articles

Towards a Pediatric Approach in Adults with Acute Lymphoblastic Leukemia (ALL): The GRAALL-2003 Study.

Blood (2006) 108 (11): 147.

https://doi.org/10.1182/blood.V108.11.147.147

Published: 2006

NARROW

Second TKI Discontinuation in CML Patients That Failed First Discontinuation and Subsequently Regained Deep Molecular Response after TKI Re-Challenge

Dasatinib or Nilotinib Discontinuation in Chronic Phase (CP)-Chronic Myeloid Leukemia (CML) Patients (pts) with Durably Undetectable BCR-ABL Transcripts: Interim Analysis of the STOP 2G-TKI Study with a Minimum Follow-up of 12 Months – on Behalf of the French CML Group Filmc

Preliminary Report Of The STIM2 Study: A Multicenter Stop Imatinib Trial For Chronic Phase Chronic Myeloid Leukemia De Novo Patients On Imatinib

Post-Remission Therapy with Imatinib and HAM Improve MRD before Tansplant for Patients with Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ALL): Results of the GRAALL AFR03 Study.

Towards a Pediatric Approach in Adults with Acute Lymphoblastic Leukemia (ALL): The GRAALL-2003 Study.

Email alerts

ASH Publications

American Society of Hematology

Second TKI Discontinuation in CML Patients That Failed First Discontinuation and Subsequently Regained Deep Molecular Response after TKI Re-Challenge

Dasatinib or Nilotinib Discontinuation in Chronic Phase (CP)-Chronic Myeloid Leukemia (CML) Patients (pts) with Durably Undetectable BCR-ABL Transcripts: Interim Analysis of the STOP 2G-TKI Study with a Minimum Follow-up of 12 Months – on Behalf of the French CML Group Filmc

Preliminary Report Of The STIM2 Study: A Multicenter Stop Imatinib Trial For Chronic Phase Chronic Myeloid Leukemia De Novo Patients On Imatinib

Post-Remission Therapy with Imatinib and HAM Improve MRD before Tansplant for Patients with Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ALL): Results of the GRAALL AFR03 Study.

Towards a Pediatric Approach in Adults with Acute Lymphoblastic Leukemia (ALL): The GRAALL-2003 Study.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only